Genetic basis for personalized medicine in asthma
| Autor: | Michael A. Portelli, Ian Sayers |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Pulmonary and Respiratory Medicine
Leukotriene Polymorphism Genetic business.industry Public Health Environmental and Occupational Health IL1RL1 Disease Precision medicine medicine.disease Bioinformatics Asthma Clinical trial Pharmacogenetics Immunology medicine Humans Immunology and Allergy Anti-Asthmatic Agents Personalized medicine Precision Medicine business |
| Zdroj: | Expert Review of Respiratory Medicine. 6:223-236 |
| ISSN: | 1747-6356 1747-6348 |
| Popis: | There is heterogeneity in patient responses to current asthma medications. Significant progress has been made identifying genetic polymorphisms that influence the efficacy and potential for adverse effects to asthma drugs, including; β(2)-adrenergic receptor agonists, corticosteroids and leukotriene modifiers. Pharmacogenetics holds great promise to maximise clinical outcomes and minimize adverse effects. Asthma is heterogeneous with respect to clinical presentation and inflammatory mechanisms underlying the disease, which is likely to contribute to variable results in clinical trials targeting specific inflammatory mediators. Genome-wide association studies have begun to identify genes underlying asthma (e.g., IL1RL1), which represent future therapeutic targets. In this article, we review and update the pharmacogenetics of current asthma therapies and discuss the genetics underlying selected Phase II and future targets. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|